Company Showcase Musculoskeletal system and connective tissue

WuXi AppTec&AZ

WuXi AppTec&AZ is a joint venture between AstraZeneca’s subsidiary MedImmune and Shanghai WuXi AppTec. Its main product WBP216 is a recombinant human anti-interleukin-6 monoclonal antibody for the treatment of rheumatoid arthritis. The mechanism of the product is clear, the production process is stable, the administration is convenient, and it can treat diseases caused by IL-6 / IL-6R signaling pathway.

药明利康是阿斯利康子公司MedImmune与上海药明康德的合资公司。其主要产品为治疗类风湿关节炎的重组全人抗白介素-6单克隆抗体WBP216。该产品的作用机理清晰,生产工艺稳定,给药便捷,临床上可作用于IL-6/IL-6R信号通路引起的疾病治疗。